Benjamin Graham Detailed Fundamental Analysis

Validea's guru fundamental report indicates that Regeneron Pharmaceuticals (REGN) scores 71% using its Benjamin Graham Value Investor model, the highest among 22 strategies tracked. While REGN, a large-cap growth stock, passes key fundamental criteria such as sales, debt, and long-term EPS growth, its P/E and Price/Book ratios fail the strict deep value requirements of the Graham methodology, placing it below the 80% threshold for 'some interest' despite its operational strengths.

Analysis

Regeneron Pharmaceuticals (REGN) receives a mixed assessment from Validea's Benjamin Graham-based value investing model, scoring 71%, which is below the 80% threshold indicating significant interest from the strategy. The analysis highlights a clear dichotomy: while REGN, a large-cap growth stock, demonstrates strong underlying business fundamentals by passing stringent criteria for sales, current ratio, low long-term debt relative to net current assets, and long-term EPS growth, it fails on key valuation metrics. Specifically, its Price-to-Earnings (P/E) and Price-to-Book (P/B) ratios are too high to satisfy the deep value requirements of the Graham methodology. This suggests that while the company is operationally sound and growing, its current market valuation is not aligned with the principles of a classic value investor, reflecting a premium typically associated with growth-oriented equities.

Key Decisions for Investors

• Deep value investors following a strict Graham-style methodology should be cautious, as REGN's current P/E and P/B ratios fail the model's valuation tests despite its strong operational fundamentals.
• Investors with a 'Growth at a Reasonable Price' (GARP) or growth-focused mandate might find the strong fundamentals, such as solid EPS growth and a healthy balance sheet, to be compelling, potentially justifying the richer valuation.
• The primary consideration is the conflict between REGN's growth stock profile and its value-based assessment; potential investors must determine if its growth trajectory warrants a valuation that exceeds traditional value benchmarks.